A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
for Chronic Lymphocytic Leukemia
Drug: Ibrutinib
19 locations incl. Anaheim
Sponsor: Loxo Oncology, Inc.
Sex: All·Age: 18+
Code: NCT05254743·Phase 3·Recruiting